{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:20:27Z","timestamp":1791231627066,"version":"4.1.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012635","name":"University of Fort Hare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012635","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The build-up of beta-amyloid plaques in the brain leads to Alzheimer\u2019s disease (AD), a neurodegenerative condition. AD affects more than 30\u00a0million individuals globally every year. No cure for AD has been discovered yet. The available therapeutic options are administered to slow down the progress of the disease. The currently available treatment plans are used to relieve symptoms and improve cognitive abilities, thus slowing progression. Nanotechnology is highly effective and has demonstrated significant benefits across various medical applications. Nanoparticles have been explored as promising drug delivery systems for the targeted delivery of anti-AD therapeutics and for the precise diagnosis of the condition. Nanoparticles, such as dendrimers, lipid-based nanoparticles, polymer-based nanoparticles, and metal-based nanoparticles, have been designed and reported to inhibit A\u03b2 aggregation, fibril formation, and disaggregating mature fibrils, prevent neuroinflammation and A\u03b21-42-induced cell damage, treat oxidative stress and lower hallmark of A\u03b2, and display excellent capability to bypass blood-brain barrier (BBB). This review is focused on the preclinical therapeutic outcomes of nanoparticles and the challenges encountered in the treatment of AD. This review highlights the significant advancements of nanoparticles that are currently undergoing clinical trials for management of AD.<\/jats:p>","DOI":"10.1007\/s13760-025-02905-w","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:01:38Z","timestamp":1760367698000},"page":"35-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The therapeutic efficacy of nanoparticles in the treatment of alzheimer\u2019s disease"],"prefix":"10.1007","volume":"126","author":[{"given":"Thabisa L.","family":"Ntondini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobeka","family":"Naki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibusiso","family":"Alven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2905_CR1","doi-asserted-by":"publisher","unstructured":"Gholami A Alzheimer\u2019s disease: the role of proteins in formation, mechanisms, and new therapeutic approaches. Neurosci Lett .2023;817. https:\/\/doi.org\/10.1016\/j.neulet.2023.137532","DOI":"10.1016\/j.neulet.2023.137532"},{"key":"2905_CR2","doi-asserted-by":"publisher","unstructured":"Fu D, Liu D, Zhang L, Sun L (2020) Self-assembled fluorescent tripeptide nanoparticles for bioimaging and drug delivery applications. Chin Chem Lett 31. https:\/\/doi.org\/10.1016\/j.cclet.2020.07.011","DOI":"10.1016\/j.cclet.2020.07.011"},{"key":"2905_CR3","doi-asserted-by":"publisher","DOI":"10.1109\/access.2023.3244952","author":"FMJM Shamrat","year":"2023","unstructured":"Shamrat FMJM, Akter S, Azam S, Karim A, Ghosh P, Tasnim Z et al (2023) AlzheimerNet: an effective deep learning based proposition for alzheimer\u2019s disease stages classification from functional brain changes in magnetic resonance images. IEEE Access. https:\/\/doi.org\/10.1109\/access.2023.3244952","journal-title":"IEEE Access"},{"key":"2905_CR4","doi-asserted-by":"publisher","unstructured":"Watt AD, Jenkins NL, McColl G, Collins S, Desmond PM (2019) Ethical issues in the treatment of late-stage alzheimer\u2019s disease. J Alzheimer\u2019s Dis 68. https:\/\/doi.org\/10.3233\/jad-180865","DOI":"10.3233\/jad-180865"},{"key":"2905_CR5","doi-asserted-by":"publisher","unstructured":"Gustavsson A, Norton N, Fast T, Fr\u00f6lich L, Georges J, Holzapfel D et al (2023) Global estimates on the number of persons across the alzheimer\u2019s disease continuum. Alzheimer\u2019s Dement 19. https:\/\/doi.org\/10.1002\/alz.12694","DOI":"10.1002\/alz.12694"},{"key":"2905_CR6","doi-asserted-by":"publisher","unstructured":"Knopman DS, Amieva H, Petersen RC, Ch\u00e9telat G, Holtzman DM, Hyman BT et al (2021) Alzheimer Disease Nat Rev Dis Primers 7. https:\/\/doi.org\/10.1038\/s41572-021-00269-y","DOI":"10.1038\/s41572-021-00269-y"},{"key":"2905_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-5416-4_14","author":"VJ De-Paula","year":"2012","unstructured":"De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV (2012) Alzheimer\u2019s disease. Subcell Biochem. https:\/\/doi.org\/10.1007\/978-94-007-5416-4_14","journal-title":"Subcell Biochem"},{"key":"2905_CR8","doi-asserted-by":"publisher","unstructured":"Armstrong RA (2019) Risk factors for alzheimer\u2019s disease. Folia Neuropathol 57. https:\/\/doi.org\/10.5114\/fn.2019.85929","DOI":"10.5114\/fn.2019.85929"},{"key":"2905_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-013-0036-3","author":"P Anand","year":"2013","unstructured":"Anand P, Singh B (2013) A review on cholinesterase inhibitors for alzheimer\u2019s disease. Arch Pharm Res. https:\/\/doi.org\/10.1007\/s12272-013-0036-3","journal-title":"Arch Pharm Res"},{"key":"2905_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245789","author":"Z Breijyeh","year":"2020","unstructured":"Breijyeh Z, Karaman R (2020) Comprehensive review on alzheimer\u2019s disease: causes and treatment. Molecules. https:\/\/doi.org\/10.3390\/molecules25245789","journal-title":"Molecules"},{"key":"2905_CR11","doi-asserted-by":"publisher","unstructured":"Eldufani J, Blaise G (2019) The role of acetylcholinesterase inhibitors such as neostigmine and Rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications. Alzheimer\u2019s Dement Transl Res Clin Interv 5. https:\/\/doi.org\/10.1016\/j.trci.2019.03.004","DOI":"10.1016\/j.trci.2019.03.004"},{"key":"2905_CR12","doi-asserted-by":"publisher","unstructured":"Sharma K (2019) Cholinesterase inhibitors as alzheimer\u2019s therapeutics. Mol Med Rep 20. https:\/\/doi.org\/10.3892\/mmr.2019.10374","DOI":"10.3892\/mmr.2019.10374"},{"key":"2905_CR13","doi-asserted-by":"publisher","unstructured":"Zhang Y, Geng R, Liu M, Deng S, Ding J, Zhong H et al (2023) Shared peripheral blood biomarkers for alzheimer\u2019s disease, major depressive disorder, and type 2 diabetes and cognitive risk factor analysis. Heliyon 9. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e14653","DOI":"10.1016\/j.heliyon.2023.e14653"},{"key":"2905_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2020.1736208","author":"DT Pham","year":"2020","unstructured":"Pham DT, Tiyaboonchai W (2020) Fibroin nanoparticles: A promising drug delivery system. Drug Deliv. https:\/\/doi.org\/10.1080\/10717544.2020.1736208. 27","journal-title":"Drug Deliv"},{"key":"2905_CR15","doi-asserted-by":"publisher","unstructured":"Hsu CY, Rheima AM, Kadhim MM, Ahmed NN, Mohammed SH, Abbas FH et al (2023) An overview of nanoparticles in drug delivery: properties and applications. South Afr J Chem Eng 46. https:\/\/doi.org\/10.1016\/j.sajce.2023.08.009","DOI":"10.1016\/j.sajce.2023.08.009"},{"key":"2905_CR16","doi-asserted-by":"publisher","unstructured":"Fonseca-Santos B, Gremi\u00e3o MPD, Chorilli M (2015) Nanotechnology-based drug delivery systems for the treatment of alzheimer\u2019s disease. Int J Nanomed 10. https:\/\/doi.org\/10.2147\/IJN.S87148","DOI":"10.2147\/IJN.S87148"},{"key":"2905_CR17","doi-asserted-by":"publisher","unstructured":"Gomes MJ, das Neves J, Sarmento B (2014) Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomed 9. https:\/\/doi.org\/10.2147\/IJN.S45886","DOI":"10.2147\/IJN.S45886"},{"key":"2905_CR18","doi-asserted-by":"publisher","unstructured":"Satalkar P, Elger BS, Hunziker P, Shaw D (2016) Challenges of clinical translation in nanomedicine: A qualitative study. Nanomed Nanatechnol Biol Med 12. https:\/\/doi.org\/10.1016\/j.nano.2015.12.376","DOI":"10.1016\/j.nano.2015.12.376"},{"key":"2905_CR19","doi-asserted-by":"publisher","unstructured":"Pardo-Moreno T, Gonz\u00e1lez-Acedo A, Rivas-Dom\u00ednguez A, Garc\u00eda-Morales V, Garc\u00eda-Cozar FJ, Ramos-Rodr\u00edguez JJ et al (2022) Therapeutic approach to alzheimer\u2019s disease: current treatments and new perspectives. Pharmaceutics 14. https:\/\/doi.org\/10.3390\/pharmaceutics14061117","DOI":"10.3390\/pharmaceutics14061117"},{"key":"2905_CR20","doi-asserted-by":"publisher","unstructured":"Larkin HD (2022) First donepezil transdermal patch approved for alzheimer disease. JAMA 327. https:\/\/doi.org\/10.1001\/jama.2022.6662","DOI":"10.1001\/jama.2022.6662"},{"key":"2905_CR21","doi-asserted-by":"publisher","unstructured":"Yiannopoulou KG, Papageorgiou SG (2020) Current and future treatments in alzheimer disease: an update. J Cent Nerv Syst Dis 12. https:\/\/doi.org\/10.1177\/1179573520907397","DOI":"10.1177\/1179573520907397"},{"key":"2905_CR22","doi-asserted-by":"publisher","unstructured":"Kabir MT, Sufian MA, Uddin MS, Begum M, Akhter S, Islam A et al (2019) NMDA receptor antagonists: repositioning of memantine as a multitargeting agent for alzheimer\u2019s therapy. Curr Pharm Des 25. https:\/\/doi.org\/10.2174\/1381612825666191011102444","DOI":"10.2174\/1381612825666191011102444"},{"key":"2905_CR23","doi-asserted-by":"publisher","unstructured":"Matsunaga S, Kishi T, Nomura I, Sakuma K, Okuya M, Ikuta T et al (2018) The efficacy and safety of memantine for the treatment of alzheimer\u2019s disease. Expert Opin Drug Saf 17. https:\/\/doi.org\/10.1080\/14740338.2018.1524870","DOI":"10.1080\/14740338.2018.1524870"},{"key":"2905_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2003.tb00254.x","author":"MA Rogawski","year":"2003","unstructured":"Rogawski MA, Wenk GL (2003) The neuropharmacological basis for the use of memantine in the treatment of alzheimer\u2019s disease. CNS Drug Rev. https:\/\/doi.org\/10.1111\/j.1527-3458.2003.tb00254.x. 9","journal-title":"CNS Drug Rev"},{"key":"2905_CR25","doi-asserted-by":"publisher","unstructured":"Lipton SA (2005) The molecular basis of memantine action in alzheimer\u2019s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2. https:\/\/doi.org\/10.2174\/1567205053585846","DOI":"10.2174\/1567205053585846"},{"key":"2905_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13035","author":"A Adlimoghaddam","year":"2018","unstructured":"Adlimoghaddam A, Neuendorff M, Roy B, Albensi BC (2018) A review of clinical treatment considerations of donepezil in severe Alzheimer\u2019s disease. CNS Neurosci Ther. https:\/\/doi.org\/10.1111\/cns.13035","journal-title":"CNS Neurosci Ther"},{"key":"2905_CR27","doi-asserted-by":"publisher","unstructured":"Hong YJ, Han HJ, Youn YC, Park KW, Yang DW, Kim S et al (2019) Safety and tolerability of donepezil 23\u00a0mg with or without intermediate dose titration in patients with Alzheimer\u2019s disease taking donepezil 10\u00a0mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial. Alzheimers Res Ther 11. https:\/\/doi.org\/10.1186\/s13195-019-0492-1","DOI":"10.1186\/s13195-019-0492-1"},{"key":"2905_CR28","unstructured":"Kumar A, Sidhu J, Goyal A, Tsao JW, Doerr C (2021) Alzheimer disease (nursing).Stat Pearls"},{"key":"2905_CR29","unstructured":"Kalola UK, Nguyen H (2021) Galantamine. Stat Pearls"},{"key":"2905_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s40828-017-0043-y","author":"B Janssen","year":"2017","unstructured":"Janssen B, Sch\u00e4fer B, Galantamine (2017) ChemTexts. https:\/\/doi.org\/10.1007\/s40828-017-0043-y","journal-title":"ChemTexts"},{"key":"2905_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3452002.tb00221.x","author":"S Lilienfeld","year":"2002","unstructured":"Lilienfeld S (2002) Galantamine\u2014a novel cholinergic drug with a unique dual mode of action for the treatment of patients with alzheimer\u2019s disease. CNS Drug Rev. https:\/\/doi.org\/10.1111\/j.1527-3458.2002.tb00221.x","journal-title":"CNS Drug Rev"},{"key":"2905_CR32","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2080-16.2016","author":"KV Kastanenka","year":"2016","unstructured":"Kastanenka KV, Bussiere T, Shakerdge N, Qian F, Weinreb PH, Rhodes K et al (2016) Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice. J Neurosci. https:\/\/doi.org\/10.1523\/JNEUROSCI.2080-16.2016","journal-title":"J Neurosci"},{"key":"2905_CR33","doi-asserted-by":"publisher","unstructured":"Rahman A, Hossen MA, Chowdhury MFI, Bari S, Tamanna N, Sultana SS et al (2023) Aducanumab for the treatment of alzheimer\u2019s disease: a systematic review. Psychogeriatrics 23. https:\/\/doi.org\/10.1111\/psyg.12944","DOI":"10.1111\/psyg.12944"},{"key":"2905_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-021-01125-y","author":"D Boris","year":"2021","unstructured":"Boris D, Fadel B, Pope ED III, Shi J, Mari Z, Sabbagh MN (2021) Critical appraisal of amyloid lowering agents in AD. Curr Neurol Neurosci Rep. https:\/\/doi.org\/10.1007\/s11910-021-01125-y","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2905_CR35","doi-asserted-by":"publisher","unstructured":"Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW et al (2018) Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2. Sci Rep 8. https:\/\/doi.org\/10.1038\/s41598-018-24501-0","DOI":"10.1038\/s41598-018-24501-0"},{"key":"2905_CR36","doi-asserted-by":"publisher","unstructured":"Guo H, Wang G, Zhai Z, Huang J, Huang Z, Zhou Y et al (2024) Rivastigmine nasal spray for the treatment of alzheimer\u2019s disease: olfactory deposition and brain delivery. Int J Pharm 652. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.123809","DOI":"10.1016\/j.ijpharm.2024.123809"},{"key":"2905_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001191.pub4","author":"JS Birks","year":"2015","unstructured":"Birks JS, Evans JG (2015) Rivastigmine for alzheimer\u2019s disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001191.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"2905_CR38","doi-asserted-by":"publisher","DOI":"10.2147\/nedt.2007.3.2.211","author":"T M\u00fcller","year":"2007","unstructured":"M\u00fcller T (2007) Rivastigmine in the treatment of patients with alzheimer\u2019s disease. Neuropsychiatr Dis Treat. https:\/\/doi.org\/10.2147\/nedt.2007.3.2.211","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2905_CR39","doi-asserted-by":"publisher","unstructured":"Takahashi JA, Sande D, da Silva Lima G, e Moura MAF, Lima MTNS (2019) Fungal metabolites as promising new drug leads for the treatment of alzheimer\u2019s disease. Stud Nat Prod Chem 62. https:\/\/doi.org\/10.1016\/B978-0-444-64185-4.00001-0","DOI":"10.1016\/B978-0-444-64185-4.00001-0"},{"key":"2905_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-013-9608-0","author":"NJ Abbott","year":"2013","unstructured":"Abbott NJ (2013) Blood\u2013brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. https:\/\/doi.org\/10.1007\/s10545-013-9608-0","journal-title":"J Inherit Metab Dis"},{"key":"2905_CR41","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020412","author":"R Daneman","year":"2015","unstructured":"Daneman R, Prat A (2015) The blood\u2013brain barrier. Cold Spring Harb Perspect Biol. https:\/\/doi.org\/10.1101\/cshperspect.a020412","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2905_CR42","doi-asserted-by":"publisher","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y The blood\u2013brain barrier: structure, regulation, and drug delivery. 8, Signal Transduction and Targeted Therapy. Springer Nature.2023;8. https:\/\/doi.org\/10.1038\/s41392-023-01481-w","DOI":"10.1038\/s41392-023-01481-w"},{"key":"2905_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2019.11.009","author":"R Pandit","year":"2020","unstructured":"Pandit R, Chen L, G\u00f6tz J (2020) The blood-brain barrier: physiology and strategies for drug delivery. Adv Drug Deliv Rev. https:\/\/doi.org\/10.1016\/j.addr.2019.11.009","journal-title":"Adv Drug Deliv Rev"},{"key":"2905_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2013.135","author":"MA Erickson","year":"2013","unstructured":"Erickson MA, Banks WA (2013) Blood\u2013brain barrier dysfunction as a cause and consequence of Alzheimer\u2019s disease. J Cereb Blood Flow Metab. https:\/\/doi.org\/10.1038\/jcbfm.2013.135","journal-title":"J Cereb Blood Flow Metab"},{"key":"2905_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.12.005","author":"WA Banks","year":"2012","unstructured":"Banks WA (2012) Drug delivery to the brain in Alzheimer\u2019s disease: consideration of the blood\u2013brain barrier. Adv Drug Deliv Rev. https:\/\/doi.org\/10.1016\/j.addr.2011.12.005","journal-title":"Adv Drug Deliv Rev"},{"key":"2905_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00021","author":"S Luo","year":"2020","unstructured":"Luo S, Ma C, Zhu MQ, Ju WN, Yang Y, Wang X (2020) Application of iron oxide nanoparticles in the diagnosis and treatment of neurodegenerative diseases with emphasis on Alzheimer\u2019s disease. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2020.00021","journal-title":"Front Cell Neurosci"},{"key":"2905_CR47","doi-asserted-by":"publisher","unstructured":"Madara JL (1998) Regulation of the movement of solutes across tight junctions. Annu Rev Physiol 60. https:\/\/doi.org\/10.1146\/annurev.physiol.60.1.143","DOI":"10.1146\/annurev.physiol.60.1.143"},{"key":"2905_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/00970002042006005","author":"MN Martinez","year":"2002","unstructured":"Martinez MN, Amidon GL (2002) A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. https:\/\/doi.org\/10.1177\/00970002042006005","journal-title":"J Clin Pharmacol"},{"key":"2905_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/0169-409X(95)00005-R","author":"U Bickel","year":"1995","unstructured":"Bickel U (1995) Antibody delivery through the blood-brain barrier. Adv Drug Deliv Rev. 15.https:\/\/https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/0169-409X(95)00005-R","journal-title":"Adv Drug Deliv Rev"},{"key":"2905_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/2.4.355","author":"GR Hayes","year":"1992","unstructured":"Hayes GR, Enns CA, Lucas JJ (1992) Identification of the O-linked glycosylation site of the human transferrin receptor. Glycobiology. https:\/\/doi.org\/10.1093\/glycob\/2.4.355","journal-title":"Glycobiology"},{"key":"2905_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-020-00230-3","author":"H Kadry","year":"2020","unstructured":"Kadry H, Noorani B, Cucullo L (2020) A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. https:\/\/doi.org\/10.1186\/s12987-020-00230-3","journal-title":"Fluids Barriers CNS"},{"key":"2905_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14482","author":"AS Haqqani","year":"2018","unstructured":"Haqqani AS, Thom G, Burrell M, Delaney CE, Brunette E, Baumann E et al (2018) Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood\u2013brain barrier in vitro is dependent on its binding affinity. J Neurochem. https:\/\/doi.org\/10.1111\/jnc.14482","journal-title":"J Neurochem"},{"key":"2905_CR53","unstructured":"Alberts B (2002) Molecular biology of the cell 4th edition. (No Title)"},{"key":"2905_CR54","doi-asserted-by":"publisher","DOI":"10.1021\/ja073522o","author":"M Teixid\u00f3","year":"2007","unstructured":"Teixid\u00f3 M, Zurita E, Malakoutikhah M, Tarrag\u00f3 T, Giralt E (2007) Diketopiperazines as a tool for the study of transport across the blood\u2009\u2013\u2009brain barrier (BBB) and their potential use as BBB-shuttles. J Am Chem Soc. https:\/\/doi.org\/10.1021\/ja073522o","journal-title":"J Am Chem Soc"},{"key":"2905_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/jlcr.3442","author":"A Virgone-Carlotta","year":"2016","unstructured":"Virgone-Carlotta A, Dufour E, Bacot S, Ahmadi M, Cornou M, Moni L et al (2016) New diketopiperazines as vectors for peptide protection and brain delivery: synthesis and biological evaluation. J Label Compd Radiopharm. https:\/\/doi.org\/10.1002\/jlcr.3442","journal-title":"J Label Compd Radiopharm"},{"key":"2905_CR56","doi-asserted-by":"publisher","DOI":"10.2174\/1567201816666191029122740","author":"K Kashyap","year":"2019","unstructured":"Kashyap K, Shukla R (2019) Drug delivery and targeting to the brain through nasal route: mechanisms, applications and challenges. Curr Drug Deliv. https:\/\/doi.org\/10.2174\/1567201816666191029122740","journal-title":"Curr Drug Deliv"},{"key":"2905_CR57","doi-asserted-by":"publisher","DOI":"10.2174\/187221108784534081","author":"KK Sawant","year":"2008","unstructured":"Sawant KK, Dodiya SS (2008) Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv Formul. https:\/\/doi.org\/10.2174\/187221108784534081","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"2905_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201705328","author":"OS Fenton","year":"2018","unstructured":"Fenton OS, Olafson KN, Pillai PS, Mitchell MJ, Langer R (2018) Advances in biomaterials for drug delivery. Adv Mater. https:\/\/doi.org\/10.1002\/adma.201705328","journal-title":"Adv Mater"},{"key":"2905_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/s0169-409x(02)00118-7","author":"RH M\u00fcller","year":"2002","unstructured":"M\u00fcller RH, Radtke M, Wissing SA (2002) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. https:\/\/doi.org\/10.1016\/s0169-409x(02)00118-7","journal-title":"Adv Drug Deliv Rev"},{"key":"2905_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-64056-7.00006-4","author":"D Stanisic","year":"2018","unstructured":"Stanisic D, Costa AF, Cruz G, Dur\u00e1n N, Tasic L (2018) Applications of flavonoids, with an emphasis on hesperidin, as anticancer prodrugs: phytotherapy as an alternative to chemotherapy. Stud Nat Prod Chem. https:\/\/doi.org\/10.1016\/B978-0-444-64056-7.00006-4","journal-title":"Stud Nat Prod Chem"},{"key":"2905_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100701","author":"SS Naser","year":"2023","unstructured":"Naser SS, Singh D, Preetam S, Kishore S, Kumar L, Nandi A et al (2023) Posterity of nanoscience as lipid nanosystems for alzheimer\u2019s disease regression. Mater Today Bio. https:\/\/doi.org\/10.1016\/j.mtbio.2023.100701","journal-title":"Mater Today Bio"},{"key":"2905_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11101863","author":"A Campisi","year":"2022","unstructured":"Campisi A, Sposito G, Pellitteri R, Santonocito D, Bisicchia J, Raciti G et al (2022) Effect of unloaded and curcumin-loaded solid lipid nanoparticles on tissue transglutaminase isoforms expression levels in an experimental model of Alzheimer\u2019s disease. Antioxidants. https:\/\/doi.org\/10.3390\/antiox11101863","journal-title":"Antioxidants"},{"key":"2905_CR63","doi-asserted-by":"publisher","unstructured":"Mir Najib Ullah SN, Afzal O, Altamimi ASA, Ather H, Sultana S, Almalki WH et al (2023) Nanomedicine in the management of alzheimer\u2019s disease: State-of-the-art. Biomedicines 11. https:\/\/doi.org\/10.3390\/biomedicines11061752","DOI":"10.3390\/biomedicines11061752"},{"key":"2905_CR64","doi-asserted-by":"publisher","DOI":"10.5958\/0974-360X.2018.00523.1","author":"M Yasir","year":"2018","unstructured":"Yasir M, Chauhan I, Haji MJ, Tura AJ, Saxena PK (2018) Formulation and evaluation of glyceryl behenate based solid lipid nanoparticles for the delivery of donepezil to brain through nasal route. Res J Pharm Technol. https:\/\/doi.org\/10.5958\/0974-360X.2018.00523.1","journal-title":"Res J Pharm Technol"},{"key":"2905_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010038","author":"GR Topal","year":"2020","unstructured":"Topal GR, M\u00e9sz\u00e1ros M, Porkol\u00e1b G, Szecsk\u00f3 A, Polg\u00e1r TF, Sikl\u00f3s L et al (2020) ApoE-targeting increases the transfer of solid lipid nanoparticles with donepezil cargo across a culture model of the blood\u2013brain barrier. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics13010038","journal-title":"Pharmaceutics"},{"key":"2905_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2019.107082","author":"T Dara","year":"2019","unstructured":"Dara T, Vatanara A, Sharifzadeh M, Khani S, Vakilinezhad MA, Vakhshiteh F et al (2019) Improvement of memory deficits in the rat model of alzheimer\u2019s disease by erythropoietin-loaded solid lipid nanoparticles. Neurobiol Learn Mem. https:\/\/doi.org\/10.1016\/j.nlm.2019.107082","journal-title":"Neurobiol Learn Mem"},{"key":"2905_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2019.104794","author":"MK Chauhan","year":"2019","unstructured":"Chauhan MK, Sharma PK (2019) Optimization and characterization of Rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia. Chem Phys Lipids. https:\/\/doi.org\/10.1016\/j.chemphyslip.2019.104794","journal-title":"Chem Phys Lipids"},{"key":"2905_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2019.02.007","author":"IT Mendes","year":"2019","unstructured":"Mendes IT, Ruela ALM, Carvalho FC, Freitas JTJ, Bonfilio R, Pereira GR (2019) Development and characterization of nanostructured lipid carrier-based gels for the transdermal delivery of donepezil. Colloids Surf B Biointerfaces. https:\/\/doi.org\/10.1016\/j.colsurfb.2019.02.007","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2905_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105314","author":"RGR Pinheiro","year":"2020","unstructured":"Pinheiro RGR, Granja A, Loureiro JA, Pereira MC, Pinheiro M, Neves AR et al (2020) Quercetin lipid nanoparticles functionalized with transferrin for alzheimer\u2019s disease. Eur J Pharm Sci. https:\/\/doi.org\/10.1016\/j.ejps.2020.105314","journal-title":"Eur J Pharm Sci"},{"key":"2905_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040835","author":"P Poudel","year":"2022","unstructured":"Poudel P, Park S (2022) Recent advances in the treatment of alzheimer\u2019s disease using nanoparticle-based drug delivery systems. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14040835","journal-title":"Pharmaceutics"},{"key":"2905_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1228679","author":"L Hu","year":"2023","unstructured":"Hu L, Tao Y, Jiang Y, Qin F (2023) Recent progress of nanomedicine in the treatment of Alzheimer\u2019s disease. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2023.1228679","journal-title":"Front Cell Dev Biol"},{"key":"2905_CR72","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-00908-7","author":"M Plaza-Oliver","year":"2021","unstructured":"Plaza-Oliver M, Santander-Ortega MJ, Lozano MV (2021) Current approaches in lipid-based nanocarriers for oral drug delivery. Drug Deliv Transl Res. https:\/\/doi.org\/10.1007\/s13346-021-00908-7","journal-title":"Drug Deliv Transl Res"},{"key":"2905_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.02.012","author":"CP Costa","year":"2021","unstructured":"Costa CP, Moreira JN, Lobo JMS, Silva AC (2021) Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies. Acta Pharm Sin B. https:\/\/doi.org\/10.1016\/j.apsb.2021.02.012","journal-title":"Acta Pharm Sin B"},{"key":"2905_CR74","doi-asserted-by":"publisher","unstructured":"Al-Maghrabi PM, Khafagy ES, Ghorab MM, Gad S (2020) Influence of formulation variables on miconazole nitrate\u2013loaded lipid based nanocarrier for topical delivery. Colloids Surf B Biointerfaces 193. https:\/\/doi.org\/10.1016\/j.colsurfb.2020.111046","DOI":"10.1016\/j.colsurfb.2020.111046"},{"key":"2905_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.01.040","author":"AP Rajput","year":"2019","unstructured":"Rajput AP, Butani SB (2019) Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: Formulation, optimization and in vivo characterization. J Drug Deliv Sci Technol. https:\/\/doi.org\/10.1016\/j.jddst.2019.01.040","journal-title":"J Drug Deliv Sci Technol"},{"key":"2905_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-019-01209-3","author":"M Casati","year":"2020","unstructured":"Casati M, Boccardi V, Ferri E, Bertagnoli L, Bastiani P, Ciccone S et al (2020) Vitamin E and Alzheimer\u2019s disease: the mediating role of cellular aging. Aging Clin Exp Res. https:\/\/doi.org\/10.1007\/s40520-019-01209-3","journal-title":"Aging Clin Exp Res"},{"key":"2905_CR77","doi-asserted-by":"publisher","unstructured":"Cunha S, Costa CP, Loureiro JA, Alves J, Peixoto AF, Forbes B et al (2020) Double optimization of rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by design (QbD) approach: formulation variables and instrumental parameters. Pharmaceutics 12. https:\/\/doi.org\/10.3390\/pharmaceutics12070599","DOI":"10.3390\/pharmaceutics12070599"},{"key":"2905_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.08.024","author":"P Wavikar","year":"2017","unstructured":"Wavikar P, Pai R, Vavia P (2017) Nose to brain delivery of Rivastigmine by in situ gelling cationic nanostructured lipid carriers: enhanced brain distribution and pharmacodynamics. J Pharm Sci. https:\/\/doi.org\/10.1016\/j.xphs.2017.08.024","journal-title":"J Pharm Sci"},{"key":"2905_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.05.609","author":"S Sood","year":"2013","unstructured":"Sood S, Jain K, Gowthamarajan K (2013) P1\u2013382: Curcumin-donepezil\u2013loaded nanostructured lipid carriers for intranasal delivery in an alzheimer\u2019s disease model. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1016\/j.jalz.2013.05.609. 9","journal-title":"Alzheimer\u2019s Dement"},{"key":"2905_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2015.06.054","author":"O Gartziandia","year":"2015","unstructured":"Gartziandia O, Herran E, Pedraz JL, Carro E, Igartua M, Hernandez RM (2015) Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf B Biointerfaces. https:\/\/doi.org\/10.1016\/j.colsurfb.2015.06.054","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2905_CR81","doi-asserted-by":"publisher","unstructured":"Sadegh Malvajerd S, Izadi Z, Azadi A, Kurd M, Derakhshankhah H, Sharifzadeh M et al (2019) Neuroprotective potential of curcumin-loaded nanostructured lipid carrier in an animal model of alzheimer\u2019s disease: behavioral and biochemical evidence. J Alzheimer\u2019s Dis 69. https:\/\/doi.org\/10.3233\/JAD-190083","DOI":"10.3233\/JAD-190083"},{"key":"2905_CR82","doi-asserted-by":"publisher","unstructured":"Ullah SNMN, Afzal O, Altamimi ASA, Ather H, Sultana S, Almalki WH et al (2023) Nanomedicine in the management of alzheimer\u2019s disease: State-of-the-art. Biomedicines 11. https:\/\/doi.org\/10.3390\/biomedicines11061752","DOI":"10.3390\/biomedicines11061752"},{"key":"2905_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117394","author":"P Nirale","year":"2020","unstructured":"Nirale P, Paul A, Yadav KS (2020) Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer\u2019s, parkinson\u2019s and prion\u2019s. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2020.117394","journal-title":"Life Sci"},{"key":"2905_CR84","doi-asserted-by":"publisher","unstructured":"Suhail N, Alzahrani AK, Basha WJ, Kizilbash N, Zaidi A, Ambreen J et al (2021) Microemulsions: unique properties, Pharmacological applications, and targeted drug delivery. Front Nanotechnol 3. https:\/\/doi.org\/10.3389\/fnano.2021.754889","DOI":"10.3389\/fnano.2021.754889"},{"key":"2905_CR85","doi-asserted-by":"publisher","DOI":"10.1080\/08982104.2018.1552703","author":"RP Patil","year":"2019","unstructured":"Patil RP, Pawara DD, Gudewar CS, Tekade AR (2019) Nanostructured cubosomes in an in situ nasal gel system: an alternative approach for the controlled delivery of donepezil HCl to brain. J Liposome Res. https:\/\/doi.org\/10.1080\/08982104.2018.1552703","journal-title":"J Liposome Res"},{"key":"2905_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01221","author":"DB Kell","year":"2020","unstructured":"Kell DB, Heyden EL, Pretorius E (2020) The biology of lactoferrin, an iron-binding protein that can help defend against viruses and bacteria. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.01221","journal-title":"Front Immunol"},{"key":"2905_CR87","doi-asserted-by":"publisher","unstructured":"Kaur A, Nigam K, Srivastava S, Tyagi A, Dang S (2020) Memantine nanoemulsion: a new approach to treat alzheimer\u2019s disease. J Microencapsul 37. https:\/\/doi.org\/10.1080\/02652048.2020.1756971","DOI":"10.1080\/02652048.2020.1756971"},{"key":"2905_CR88","doi-asserted-by":"publisher","unstructured":"Kaur A, Nigam K, Bhatnagar I, Sukhpal H, Awasthy S, Shankar S et al (2020) Treatment of alzheimer\u2019s diseases using donepezil nanoemulsion: an intranasal approach. Drug Deliv Transl Res 10. https:\/\/doi.org\/10.1007\/s13346-020-00754-z","DOI":"10.1007\/s13346-020-00754-z"},{"key":"2905_CR89","doi-asserted-by":"publisher","unstructured":"DeRidder L, Sharma A, Liaw K, Sharma R, John J, Kannan S et al (2021) Dendrimer\u2013tesaglitazar conjugate induces a phenotype shift of microglia and enhances \u03b2-amyloid phagocytosis. Nanoscale 13. https:\/\/doi.org\/10.1039\/D0NR05958G","DOI":"10.1039\/D0NR05958G"},{"key":"2905_CR90","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S214657","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Liu C, Zhai W, Zhuang N, Han T, Ding Z (2019) The optimization design of lactoferrin loaded HupA nanoemulsion for targeted drug transport via intranasal route. Int J Nanomed. https:\/\/doi.org\/10.2147\/IJN.S214657","journal-title":"Int J Nanomed"},{"issue":"2","key":"2905_CR91","first-page":"104","volume":"7","author":"M Doshi","year":"2011","unstructured":"Doshi M (2011) Dendrimer and its application. Int J Pharm Sci Rev Res 7(2):104\u2013111","journal-title":"Int J Pharm Sci Rev Res"},{"key":"2905_CR92","doi-asserted-by":"publisher","unstructured":"Ockwig NW, Nenoff TM, Separation H, Rev C, Chem E, Laurent S et al (2010) Additions Corr 110. https:\/\/doi.org\/10.1021\/cr0501792","DOI":"10.1021\/cr0501792"},{"key":"2905_CR93","doi-asserted-by":"publisher","DOI":"10.52643\/jbik.v13i3.2678","author":"L Winarti","year":"2015","unstructured":"Winarti L (2015) Sistem Penghantaran Obat tertarget, macam, jenis-jenis sistem Penghantaran, Dan Aplikasinya. STOMATOGNATIC-Jurnal Kedokt Gigi. https:\/\/doi.org\/10.52643\/jbik.v13i3.2678","journal-title":"STOMATOGNATIC-Jurnal Kedokt Gigi"},{"key":"2905_CR94","doi-asserted-by":"publisher","unstructured":"De R, Mahata MK, Kim K (2022) Structure-based varieties of polymeric nanocarriers and influences of their physicochemical properties on drug delivery profiles. Adv Sci 9. https:\/\/doi.org\/10.1002\/advs.202105373","DOI":"10.1002\/advs.202105373"},{"key":"2905_CR95","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-020-01652-w","author":"DE Igart\u00faa","year":"2020","unstructured":"Igart\u00faa DE, Martinez CS, del Alonso V, Prieto S (2020) Combined therapy for Alzheimer\u2019s disease: tacrine and PAMAM dendrimers co-administration reduces the side effects of the drug without modifying its activity. AAPS PharmSciTech. https:\/\/doi.org\/10.1208\/s12249-020-01652-w","journal-title":"AAPS PharmSciTech"},{"key":"2905_CR96","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.9b00505","author":"A Gothwal","year":"2019","unstructured":"Gothwal A, Kumar H, Nakhate KT, Ajazuddin, Dutta A, Borah A et al (2019) Lactoferrin coupled lower generation PAMAM dendrimers for brain targeted delivery of memantine in aluminum-chloride-induced alzheimer\u2019s disease in mice. Bioconjug Chem. https:\/\/doi.org\/10.1021\/acs.bioconjchem.9b00505","journal-title":"Bioconjug Chem"},{"key":"2905_CR97","doi-asserted-by":"crossref","unstructured":"Jain KK (2009) Application of nanobiotechnology in cancer therapeutics. Pharm Perspect Cancer Ther. ;245\u2013268","DOI":"10.1007\/978-1-4419-0131-6_8"},{"key":"2905_CR98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1441","author":"K Cho","year":"2008","unstructured":"Cho K, Wang XU, Nie S, Chen Z, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1441","journal-title":"Clin Cancer Res"},{"key":"2905_CR99","doi-asserted-by":"publisher","unstructured":"Heinz H, Pramanik C, Heinz O, Ding Y, Mishra RK, Marchon D et al (2017) Nanoparticle decoration with surfactants: molecular interactions, assembly, and applications. Surf Sci Rep 72. https:\/\/doi.org\/10.1016\/j.surfrep.2017.02.001","DOI":"10.1016\/j.surfrep.2017.02.001"},{"key":"2905_CR100","doi-asserted-by":"crossref","unstructured":"Vasile C (2018) Polymeric nanomaterials in nanotherapeutics. Elsevier","DOI":"10.1016\/B978-0-12-813932-5.00001-7"},{"key":"2905_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.04.034","author":"P Wang","year":"2018","unstructured":"Wang P, Zheng X, Guo Q, Yang P, Pang X, Qian K et al (2018) Systemic delivery of BACE1 SiRNA through neuron-targeted nanocomplexes for treatment of alzheimer\u2019s disease. J Control Release. https:\/\/doi.org\/10.1016\/j.jconrel.2018.04.034","journal-title":"J Control Release"},{"key":"2905_CR102","doi-asserted-by":"publisher","unstructured":"Huo X, Zhang Y, Jin X, Li Y, Zhang L (2019) A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with Curcumin molecules for the Inhibition of amyloid \u03b2 aggregation in alzheimer\u2019s disease. J Photochem Photobiol B Biol 190. https:\/\/doi.org\/10.1016\/j.jphotobiol.2018.11.008","DOI":"10.1016\/j.jphotobiol.2018.11.008"},{"key":"2905_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102214","author":"M Yusuf","year":"2021","unstructured":"Yusuf M, Khan M, Alrobaian MM, Alghamdi SA, Warsi MH, Sultana S et al (2021) Brain targeted Polysorbate-80 coated PLGA thymoquinone nanoparticles for the treatment of alzheimer\u2019s disease, with biomechanistic insights. J Drug Deliv Sci Technol. https:\/\/doi.org\/10.1016\/j.jddst.2020.102214","journal-title":"J Drug Deliv Sci Technol"},{"key":"2905_CR104","doi-asserted-by":"publisher","DOI":"10.1080\/02652048.2023.2167011","author":"T Naki","year":"2023","unstructured":"Naki T, Matshe WMR, Balogun MO, Sinha Ray S, Egieyeh SA, Aderibigbe BA (2023) Polymer drug conjugates containing memantine, Tacrine and cinnamic acid: promising nanotherapeutics for the treatment of alzheimer\u2019s disease. J Microencapsul. https:\/\/doi.org\/10.1080\/02652048.2023.2167011","journal-title":"J Microencapsul"},{"key":"2905_CR105","doi-asserted-by":"publisher","unstructured":"Jeon SG, Cha MY, Kim Jil, Hwang TW, Kim KA, Kim TH et al (2019) Vitamin D-binding protein-loaded PLGA nanoparticles suppress alzheimer\u2019s disease-related pathology in 5XFAD mice. Nanomed Nanatechnol Biol Med 17. https:\/\/doi.org\/10.1016\/j.nano.2019.02.004","DOI":"10.1016\/j.nano.2019.02.004"},{"key":"2905_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030227","author":"SG Nanaki","year":"2020","unstructured":"Nanaki SG, Spyrou K, Bekiari C, Veneti P, Baroud TN, Karouta N et al (2020) Hierarchical porous carbon\u2014plla and Plga hybrid nanoparticles for intranasal delivery of galantamine for alzheimer\u2019s disease therapy. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics12030227","journal-title":"Pharmaceutics"},{"key":"2905_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.03.010","author":"A Cano","year":"2019","unstructured":"Cano A, Ettcheto M, Chang JH, Barroso E, Espina M, K\u00fchne BA et al (2019) Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)\/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe\/PS1dE9 alzheimer\u2019s disease mice model. J Control Release. https:\/\/doi.org\/10.1016\/j.jconrel.2019.03.010","journal-title":"J Control Release"},{"key":"2905_CR108","doi-asserted-by":"publisher","DOI":"10.2174\/1567201815666181004094707","author":"SK Singh","year":"2019","unstructured":"Singh SK, Mishra DN (2019) Nose to brain delivery of galantamine loaded nanoparticles: in-vivo pharmacodynamic and biochemical study in mice. Curr Drug Deliv. https:\/\/doi.org\/10.2174\/1567201815666181004094707","journal-title":"Curr Drug Deliv"},{"key":"2905_CR109","doi-asserted-by":"publisher","DOI":"10.1007\/s12010-019-03120-z","author":"CRA Mahl","year":"2020","unstructured":"Mahl CRA, Taketa TB, Rocha-Neto JBM, Almeida WP, Beppu MM (2020) Copper ion uptake by chitosan in the presence of amyloid-\u03b2 and histidine. Appl Biochem Biotechnol. https:\/\/doi.org\/10.1007\/s12010-019-03120-z","journal-title":"Appl Biochem Biotechnol"},{"key":"2905_CR110","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01240","author":"Z Liu","year":"2021","unstructured":"Liu Z, Liu Q, Zhang B, Liu Q, Fang L, Gou S (2021) Blood\u2013brain barrier permeable and no-releasing multifunctional nanoparticles for Alzheimer\u2019s disease treatment: targeting NO\/cGMP\/CREB signaling pathways. J Med Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01240","journal-title":"J Med Chem"},{"key":"2905_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2016.06.007","author":"AC Sintov","year":"2016","unstructured":"Sintov AC, Velasco-Aguirre C, Gallardo-Toledo E, Araya E, Kogan MJ (2016) Metal nanoparticles as targeted carriers circumventing the blood\u2013brain barrier. Int Rev Neurobiol. https:\/\/doi.org\/10.1016\/bs.irn.2016.06.007","journal-title":"Int Rev Neurobiol"},{"key":"2905_CR112","doi-asserted-by":"publisher","DOI":"10.4172\/2161-0525.1000384","author":"K Alaqad","year":"2016","unstructured":"Alaqad K, Saleh TA (2016) Gold and silver nanoparticles: synthesis methods, characterization routes and applications towards drugs. J Environ Anal Toxicol. https:\/\/doi.org\/10.4172\/2161-0525.1000384","journal-title":"J Environ Anal Toxicol"},{"key":"2905_CR113","doi-asserted-by":"publisher","DOI":"10.1080\/10611860400015936","author":"PR Lockman","year":"2004","unstructured":"Lockman PR, Koziara JM, Mumper RJ, Allen DD (2004) Nanoparticle surface charges alter blood\u2013brain barrier integrity and permeability. J Drug Target. https:\/\/doi.org\/10.1080\/10611860400015936","journal-title":"J Drug Target"},{"key":"2905_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18525-2","author":"K Hou","year":"2020","unstructured":"Hou K, Zhao J, Wang H, Li B, Li K, Shi X et al (2020) Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-020-18525-2","journal-title":"Nat Commun"},{"key":"2905_CR115","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-019-01780-w","author":"N Dos Santos Tramontin","year":"2020","unstructured":"Dos Santos Tramontin N, da Silva S, Arruda R, Ugioni KS, Canteiro PB, de Bem Silveira G et al (2020) Gold nanoparticles treatment reverses brain damage in alzheimer\u2019s disease model. Mol Neurobiol. https:\/\/doi.org\/10.1007\/s12035-019-01780-w","journal-title":"Mol Neurobiol"},{"key":"2905_CR116","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00622","author":"M Sanati","year":"2019","unstructured":"Sanati M, Khodagholi F, Aminyavari S, Ghasemi F, Gholami M, Kebriaeezadeh A et al (2019) Impact of gold nanoparticles on amyloid \u03b2-induced alzheimer\u2019s disease in a rat animal model: involvement of STIM proteins. ACS Chem Neurosci. https:\/\/doi.org\/10.1021\/acschemneuro.8b00622","journal-title":"ACS Chem Neurosci"},{"key":"2905_CR117","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.9b00086","author":"Y Li","year":"2019","unstructured":"Li Y, Lim E, Fields T, Wu H, Xu Y, Wang YA et al (2019) Improving sensitivity and specificity of amyloid-\u03b2 peptides and tau protein detection with antibiofouling magnetic nanoparticles for liquid biopsy of Alzheimer\u2019s disease. ACS Biomater Sci Eng. https:\/\/doi.org\/10.1021\/acsbiomaterials.9b00086","journal-title":"ACS Biomater Sci Eng"},{"key":"2905_CR118","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2020.1720649","author":"R Paliwal","year":"2020","unstructured":"Paliwal R, Paliwal SR, Kenwat R, Kurmi B, Das, Sahu MK (2020) Solid lipid nanoparticles: A review on recent perspectives and patents. Expert Opin Ther Pat. https:\/\/doi.org\/10.1080\/13543776.2020.1720649","journal-title":"Expert Opin Ther Pat"},{"key":"2905_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2019.12.014","author":"H Akel","year":"2020","unstructured":"Akel H, Ismail R, Csoka I (2020) Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer\u2019s disease. Eur J Pharm Biopharm. https:\/\/doi.org\/10.1016\/j.ejpb.2019.12.014","journal-title":"Eur J Pharm Biopharm"},{"key":"2905_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.260","author":"A Regina","year":"2008","unstructured":"Regina A, Demeule M, Lavall\u00e9e CCI, Poirier J, Gabathuler R et al (2008) Antitumour activity of ANG1005, a conjugate between Paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. https:\/\/doi.org\/10.1038\/bjp.2008.260","journal-title":"Br J Pharmacol"},{"issue":"3","key":"2905_CR121","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/2210303106666160120215857","volume":"5","author":"S Samudre","year":"2015","unstructured":"Samudre S, Tekade A, Thorve K, Jamodkar A, Parashar G, Chaudhari N (2015) Xanthan gum coated mucoadhesive liposomes for efficient nose to brain delivery of curcumin. Drug Deliv Lett 5(3):201\u2013207","journal-title":"Drug Deliv Lett"},{"key":"2905_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2012.04.012","author":"W Li","year":"2012","unstructured":"Li W, Zhou Y, Zhao N, Hao B, Wang X, Kong P (2012) Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of Galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol. https:\/\/doi.org\/10.1016\/j.etap.2012.04.012","journal-title":"Environ Toxicol Pharmacol"},{"key":"2905_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.06.018","author":"M Fernandes","year":"2021","unstructured":"Fernandes M, Lopes I, Magalh\u00e3es L, S\u00e1rria MP, Machado R, Sousa JC et al (2021) Novel concept of exosome-like liposomes for the treatment of alzheimer\u2019s disease. J Control Release. https:\/\/doi.org\/10.1016\/j.jconrel.2021.06.018","journal-title":"J Control Release"},{"key":"2905_CR124","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.327328","author":"C Hernandez","year":"2022","unstructured":"Hernandez C, Shukla S (2022) Liposome based drug delivery as a potential treatment option for Alzheimer\u2019s disease. Neural Regen Res. https:\/\/doi.org\/10.4103\/1673-5374.327328","journal-title":"Neural Regen Res"},{"key":"2905_CR125","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2691-7","author":"B Dos Santos Rodrigues","year":"2019","unstructured":"Dos Santos Rodrigues B, Kanekiyo T, Singh J (2019) ApoE-2 brain-targeted gene therapy through transferrin and penetratin tagged liposomal nanoparticles. Pharm Res. https:\/\/doi.org\/10.1007\/s11095-019-2691-7","journal-title":"Pharm Res"},{"key":"2905_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2023.113270","author":"S Andrade","year":"2023","unstructured":"Andrade S, Pereira MC, Loureiro JA (2023) Caffeic acid loaded into engineered lipid nanoparticles for Alzheimer\u2019s disease therapy. Colloids Surf B Biointerfaces. https:\/\/doi.org\/10.1016\/j.colsurfb.2023.113270","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2905_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117861","author":"PM Saffari","year":"2020","unstructured":"Saffari PM, Alijanpour S, Takzaree N, Sahebgharani M, Etemad-Moghadam S, Noorbakhsh F et al (2020) Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced alzheimer\u2019s disease model. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2020.117861","journal-title":"Life Sci"},{"key":"2905_CR128","doi-asserted-by":"publisher","unstructured":"Kong L, Li X, tao, Ni Y nan, Xiao H, he, Yao Y, jia, Wang Y et al (2020) yuan,. Transferrin-modified osthole PEGylated liposomes travel the blood-brain barrier and mitigate Alzheimer\u2019s disease-related pathology in APP\/PS-1 mice. Int J Nanomedicine. ;https:\/\/doi.org\/10.2147\/IJN.S239608","DOI":"10.2147\/IJN.S239608"},{"key":"2905_CR129","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.0c03597","author":"I Kocsis","year":"2021","unstructured":"Kocsis I, Sanna E, Hunter CA (2021) Liposome enhanced detection of amyloid protein aggregates. Org Lett. https:\/\/doi.org\/10.1021\/acs.orglett.0c03597","journal-title":"Org Lett"},{"key":"2905_CR130","doi-asserted-by":"publisher","unstructured":"Yang P, Sheng D, Guo Q, Wang P, Xu S, Qian K et al (2020) Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of alzheimer\u2019s disease. Biomaterials 238. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.119844","DOI":"10.1016\/j.biomaterials.2020.119844"},{"key":"2905_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2020.06.058","author":"MM Agwa","year":"2020","unstructured":"Agwa MM, Abdelmonsif DA, Khattab SN, Sabra S (2020) Self-assembled lactoferrin-conjugated linoleic acid micelles as an orally active targeted nanoplatform for Alzheimer\u2019s disease. Int J Biol Macromol. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.06.058","journal-title":"Int J Biol Macromol"},{"key":"2905_CR132","doi-asserted-by":"publisher","unstructured":"Reading CL, Ahlem CN, Murphy MF (2021) NM101 phase III study of NE3107 in alzheimer\u2019s disease: Rationale, design and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener Dis Manag 11. https:\/\/doi.org\/10.2217\/nmt-2021-0022","DOI":"10.2217\/nmt-2021-0022"},{"key":"2905_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179521","author":"L Webster","year":"2017","unstructured":"Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O\u2019Brien JT, Mountain G et al (2017) Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: systematic review and consensus recommendations. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0179521","journal-title":"PLoS ONE"},{"key":"2905_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0283-5","author":"PS Aisen","year":"2017","unstructured":"Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Fr\u00f6lich L et al (2017) On the path to 2025: Understanding the alzheimer\u2019s disease continuum. Alzheimers Res Ther. https:\/\/doi.org\/10.1186\/s13195-017-0283-5","journal-title":"Alzheimers Res Ther"},{"key":"2905_CR135","doi-asserted-by":"publisher","unstructured":"Kumar N, Kumar R (2013) Nanotechnology and nanomaterials in the treatment of Life-threatening diseases. https:\/\/doi.org\/10.3390\/cells12232669. William Andrew","DOI":"10.3390\/cells12232669"},{"key":"2905_CR136","doi-asserted-by":"publisher","unstructured":"Vilella A, Belletti D, Sauer AK, Hagmeyer S, Sarowar T, Masoni M, Stasiak N, Mulvihill JJE, Ruozi B, Forni F, Vandelli MA, Tosi G, Zoli M, Grabrucker AM (2018) Reduced plaque size and inflammation in the APP23 mouse model for alzheimer\u2019s disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery. J Trace Elem Med Biol 49. https:\/\/doi.org\/10.1016\/j.jtemb.2017.12.006","DOI":"10.1016\/j.jtemb.2017.12.006"},{"key":"2905_CR137","doi-asserted-by":"publisher","unstructured":"Gao F, Zhao J, Liu P, Ji D, Zhang L, Zhang M, Li Y, Xiao Y (2020) Preparation and in vitro evaluation of multi-target-directed selenium-chondroitin sulfate nanoparticles in protecting against the alzheimer\u2019s disease. Int J Biol Macromol 142. https:\/\/doi.org\/10.1016\/j.ijbiomac.2019.09.098","DOI":"10.1016\/j.ijbiomac.2019.09.098"},{"key":"2905_CR138","doi-asserted-by":"publisher","DOI":"10.1039\/d1ra01725j","author":"SS El-Hawwary","year":"2021","unstructured":"El-Hawwary SS, Abd Almaksoud HM, Saber FR, Elimam H, Sayed AM, El Raey MA, Abdelmohsen UR (2021) Green-synthesized zinc oxide nanoparticles, anti-Alzheimer potential and the metabolic profiling of Sabal Blackburniana grown in Egypt supported by molecular modelling. RSC Adv. https:\/\/doi.org\/10.1039\/d1ra01725j","journal-title":"RSC Adv"},{"key":"2905_CR139","doi-asserted-by":"crossref","unstructured":"C\u00e1ceres C, Heusser B, Garnham A, Moczko E The Major Hypotheses of Alzheimer\u2019s Disease: Related Nanotechology-Based Approaches for Its Diagnosis and Treatment.Cells.2023;12","DOI":"10.3390\/cells12232669"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02905-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-025-02905-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02905-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:54:36Z","timestamp":1773384876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-025-02905-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2905"],"URL":"https:\/\/doi.org\/10.1007\/s13760-025-02905-w","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The author(s) confidently report that there are no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure\u00a0<!--Emphasis Type='Bold' removed-->statement"}}]}}